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TObjective: Microembolic signals detected by transcranial Doppler ultrasonography
have been demonstrated to be clinically relevant in patients supported with pulsatile
left ventricular assist devices. We prospectively investigated the quantity of micro-
embolic signals in patients supported with the continuous-flow DeBakey left ven-
tricular assist device (MicroMed DeBakey VAD; MicroMed Technology, Inc,
Houston, Tex) including the refined Carmeda BioActive Surface system (Carmeda
AB, Stockholm, Sweden).
Methods: Twenty-three patients (20 male) aged 14 to 62 years supported with
DeBakey left ventricular assist devices (n  6 with Carmeda) were enrolled in this
study. Microembolic signal monitorings were performed twice weekly by insonat-
ing the middle cerebral artery for 20 minutes without and 20 minutes with oronasal
application of oxygen (6 L/min). Evidence of clinically manifest thromboembolic
events was based on regular questionnaires, clinical examinations, and results of
diagnostic procedures.
Results: Despite a low incidence of thromboembolic complications (0.24 per 100
left ventricular assist device days), 20 patients (87%) showed circulating microem-
boli. Overall, microembolic signals were found in 175 of 499 transcranial Doppler
ultrasonographic examinations (35.1%), with mean counts of 81.2  443 (range
0-5042 signals/h). Both microembolic signal prevalence (25% vs 34%, P .01) and
absolute signal counts (46.5 vs 104, P  .01) significantly declined with oxygen
delivery. There was no significant correlation between the individual microembolic
signal activity and the incidence of clinical thromboembolism or the intensity of
antihemostatic treatment. Patients supported with the Carmeda device did not show
reduced rates of clinical thromboembolization or cerebral microemboli.
Conclusion: In patients with DeBakey left ventricular assist devices, a high load of
clinically silent microemboli can be detected within the cerebral arteries despite a
low incidence of embolic complications. It needs to be investigated whether such
continuous, presumably gaseous microembolization causes cognitive or neuropsy-
chologic deficits.
Left ventricular assist devices (LVADs) have become an accepted therapy tobridge patients with severe heart failure to cardiac transplantation.1 Ad-vances in LVAD technology have not only improved clinical outcome but
have enabled better patient mobility,2 allowing LVAD use even in an outpatient
setting.3,4 Moreover, several reports have shown recovery of native ventricular
he Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 4 1159
Cardiothoracic Transplantation Thoennissen et al
TXfunction in a subgroup of patients after long-term LVAD
support.5,6 LVADs have even been proposed as a definite
treatment option for end-stage heart failure.3
Various serious complications (eg, thromboembolism,
bleeding, and infection) represent major limitations to the
widespread application of LVADs.1,7,8 The risk of throm-
boembolic events seems to be device specific, directly re-
lated to the characteristics of the blood-contacting surface.9
In the past, most patients have been treated with pulsatile
LVADs. Lately, the novel continuous-flow DeBakey
LVAD (MicroMed DeBakey VAD; MicroMed Technol-
ogy, Inc, Houston, Tex) has been developed and is be-
lieved to cause less thromboembolism because of its
chamberless and valveless design.10 The newest De-
Bakey LVAD is endowed with a covalently bonded hep-
arin surface (Carmeda system; Carmeda AB, Stockholm,
Sweden), which is intended to reduce its thrombogenicity
further. However, there are no robust diagnostic tools
enabling us to define the individual risk of LVAD-asso-
ciated complications. It has therefore not been possible
thus far to discriminate low-risk patients who may be
suitable for long-term LVAD-support from high-risk pa-
tients who rather require early heart transplantation.
During recent years, it has been recognized that micro-
embolic signals (MESs) are noninvasively detectable by
transcranial Doppler ultrasonography (TCD) in patients
with increased risk of embolic stroke.11-13 It has been shown
for various patient groups that these clinically silent micro-
emboli may possess prognostic information with respect to
future risk of thrombembolism.14 Recently, we found a
significant correlation between the quantity of MESs and
the individual risk of clinical thromboembolic complica-
tions in 20 patients supported with the Novacor N100
LVAD (Baxter Healthcare Corp, Novacor Div, Oakland,
Calif).15 In this study we present an analysis of the long-
term follow-up of 23 patients supported with the nonpulsa-
tile MicroMed DeBakey LVAD. The following questions
were addressed: (1) How many MESs are detectable in
patients with the DeBakey LVAD? (2) Do MESs represent
prognostic markers that reflect the individual risk of clinical
thromboembolization in this population? (3) Do MESs cor-
relate with type and intensity of antithrombotic treatment?
(4) Are circulating microemboli in these patients solid or
gaseous in nature?
Methods
Subjects
From July 2000 to July 2002, a total of 23 patients who had
undergone implantation of the DeBakey LVAD were enrolled in
this study. The last 6 patients were supported with the latest
developed pumps equipped with the Carmeda system. After the
purpose and protocol of this study had been explained comprehen-
sively, all patients gave informed consent. The patients had dilated
cardiomyopathy (n 12), chronic ischemic heart disease (n 10),
1160 The Journal of Thoracic and Cardiovascular Surgery ● Octand postpartum cardiomyopathy (n  1). The LVAD implantation
procedure and the perioperative management have been described
elsewhere.10,16
Antihemostatic Treatment
After implantation, all patients were effectively anticoagulated
using with (target activated partial thromboplastin time 60-80
seconds). One patient had heparin-induced thrombocytopenia and
was therefore anticoagulated with danaparoid sodium (target anti–
factor Xa 0.35 U/mL). After stabilization of the clinical situa-
tion, oral anticoagulation with phenprocoumon was started (target
international normalized ratio 2.5-3.5). In addition, oral therapy
with platelet antiaggregation drugs was initiated either with aspirin
at 100 mg/d or with the combination of aspirin at 330 mg/d and
dipyridamole at 75 mg/d. The rationale for these two differing
antiplatelet regimens was that as yet no approved therapy with
antiplatelet drugs for DeBakey LVAD patients is known to reduce
the risk of thromboembolic events. So far, varying approaches of
different antiplatelet drugs and dosages in diverse DeBakey studies
have been done (Potapov and colleauges16 no antiplatelet drugs,
Salzberg and associates17 aspirin at 100 mg/d, Vitali and col-
leagues18 100 mg/d aspirin with dipyridamole at 800 mg/d), but
without any investigation regarding the exact drug combination
and dosage for clinical use. Recently, Bonaros and coworkers19
showed the necessity of antiplatelet therapy in patients with the
DeBakey device because platelet activation markers were upregu-
lated in the postoperative period.
Six patients were discharged from the hospital with LVAD
support and were seen at least once weekly in the outpatient clinic.
In some cases, blood was drawn only once or twice weekly to
monitor the coagulation status. Therefore an attempt was made to
perform the MES monitoring on the day of the coagulation test. If
no blood was drawn on the day of the TCD examination, the blood
test closest to this TCD examination (3 days) was taken for
further statistical analysis.
MES Monitoring
Repeated MES monitoring was performed with the patient in a
supine position with a 2-channel 2-MHz probe of a commercially
available TCD machine (TC 4040; EME, U¨ berlingen, Germany).
The 40-minute examination period included 20 minutes of TCD
monitoring while the patient was breathing room air and another
20 minutes with oxygen delivery (6 L/min) by facial mask, ar-
ranged in random order. The rationale for this procedure is that in
patients with artificial heart devices, large numbers of microemboli
are gaseous and caused by cavitation processes at the rims of the
valves.20,21 Through 100% oxygen delivery at 6 L/min instead of
air at atmospheric pressure, the rate of cavitation-induced MESs
could significantly be reduced. The physiologic explanation is that
the nitrogen present in air bubbles is replaced by oxygen, and
because oxygen bubbles have a shorter life span because of oxy-
gen’s higher solubility in blood, the number of MESs reaching the
brain is strongly reduced. Thus comparison of MES counts de-
tected with and without oxygen delivery provides an estimate of
gaseous microemboli.
The main stem of the right middle cerebral artery was unilat-
erally identified through the temporal skull in a depth of 45 to 60
mm, with a sample volume kept at 10 mm. With the 2-channel
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TXprobe, MES monitoring was performed simultaneously at two
depths (45-50 and 55-60 mm) of the middle cerebral artery. Thus
true MESs (time delay of the signal appearance in accordance with
the flow direction from the proximal to the distal channel) could
be distinguished from artifact signals (simultaneous appearance
of the signal within both channels).22 The ultrasonographic data
were processed with a 128-point fast Fourier transformation
with time window overlap of at least 50%. During the entire
monitoring period, an experienced investigator was present to
watch for patient movements and to detect MESs acoustically
on-line. In addition, the MES detection software of the TCD
machine was used with a detection threshold greater than 7 dB.
Identification of MESs was in accordance with recent consensus
statements.23,24 An attempt was made to perform MES monitoring
twice weekly until the end point (transplantation or death) was
reached. In cases of severely unstable clinical situations or reduced
patient cooperation, TCD examination had to be postponed until
appropriate conditions could be regained. For ambulatory patients,
TCD monitorings were performed on the days of clinical
follow-up.
Before each TCD examination, a standardized questionnaire
was performed to disclose clinically manifest cerebral thrombo-
TABLE 1. Survey of the clinical characteristics and result
Basic characteristics Tre
o.
Age
(y) Sex
Body mass
index
(kg/m2)
Primary
heart
disease
Carmeda
system
LVAD
time (d)
Effective
anticoagulatio
(%)
1 47 M 26 ICM No 106 100
2 42 M 29 ICM No 167 90
3 18 M 23 DCM No 280 85
4 40 M 22 DCM No 245 67
5 28 M 25 DCM No 200 58
6 41 M 24 DCM No 254 72
7 46 M 34 ICM No 145 73
8 62 M 26 ICM No 81 46
9 50 M 23 ICM No 299 73
10 54 M 24 DCM No 74 72
11 57 M 25 ICM No 108 47
12 24 F 20 DCM No 60 43
13 20 M 21 DCM No 274 100
14 47 M 26 ICM No 123 64
15 56 M 24 ICM No 387 80
16 28 M 21 DCM No 421 95
17 59 M 30 DCM No 413 85
18 50 M 25 DCM Yes 134 70
19 57 M 37 ICM Yes 9 100
20 18 M 23 DCM Yes 329 73
21 14 F 22 PPCM Yes 50 22
22 42 F 29 ICM Yes 36 50
23 28 M 21 DCM Yes 54 67
ICM, Ischemic cardiomyopathy; HTX, heart transplantation; DCM, dilated c
is the percentage of time within target range (see Methods section). †Anembolic events (eg, transient focal loss of vision, sensory or motor
The Journal of Thoracicdysfunction, and speech disturbance). Furthermore, evidence of
peripheral and cerebral thromboembolic complications was based
on the regularly screened medical records and patient files. In cases
of cerebral or peripheral thromboembolism, results of the respec-
tive diagnostic procedures (eg, computed tomography of the head
and angiography of the abdominal or peripheral arteries) were
noted.
Statistical Analysis
All statistical analyses were done with SPSS 11.0 for Windows
(SPSS Inc, Chicago, Ill). Descriptive statistics were based on
standard parameters, such as mean  SD and maximum and
minimum values. For nonnormally distributed data, comparisons
of two and more groups were performed with the Mann-Whitney
and Kruskal-Wallis tests. Frequency distributions were statistically
assessed by the 2 test (with Yates correction if necessary). Linear
regression analysis and the Pearson product moment correlation
test were used to evaluate correlations between two parameters.
Results
Basic characteristics of the 23 patients are given in Table 1.
repeated MES monitoring
nt and clinical course
MES monitoring
Exams
(No.)
MESs
ntiplatelet
reatment†
(%)
Embolic
events (No.)
Patient
outcome
Prevalence
(%)
Signals/h
(mean  SD)
62 0 (0%) HTX 5 60 6.6 11.7
88 0 (0%) HTX 24 25 263.7 809.7
99 0 (0%) HTX 43 49 189.8 658
9 0 (0%) HTX 27 26 15.2 33.5
73 0 (0%) HTX 22 36 322.2 991.8
64 1 (0.4%) Death 18 0 0 0
85 0 (0%) HTX 21 33 152.6 481.2
100 0 (0%) Death 7 43 6.6 15.1
80 0 (0%) Death 11 9 0.7 2.3
92 0 (0%) Death 8 38 6.4 9.7
74 1 (0.9%) Death 6 0 0 0
43 0 (0%) Death 6 50 27.3 57.6
73 0 (0%) HTX 11 36 33.1 62.1
100 1 (0.8%) Death 11 36 54 152
24 2 (0.5%) Death 72 31 24.3 134.3
62 2 (0.5%) HTX 56 30 49.1 250.4
25 0 (0%) HTX 36 22 5.8 28.7
59 1 (0.8%) Death 33 39 70.1 259.7
0 0 (0%) Death 3 0 0 0
94 0 (0%) HTX 53 66 128.8 695.9
11 1 (2%) Death 9 33 11.3 22.4
42 0 (0%) Death 7 14 0.9 2.1
87 1 (1.9%) LVAD 10 60 11.1 23.2
myopathy; PPCM, postpartum cardiomyopathy. *Effective anticoagulation
let treatment is the percentage of time with antiplatelet therapy.s of
atme
n*
A
t
ardioThe mean duration of LVAD therapy was 188  142 days
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TX(individual range 9-421 days). Twelve patients died of mul-
tiorgan failure (n  5), intracranial bleeding (n  4), or
right heart failure (n  3). The range of time between the
onset of multiorgan failure and death was 3 to 15 days, with
a median of 6 days. Ten patients reached heart transplanta-
tion, whereas 1 patient was still receiving LVAD support at
study’s closure. In 78% of the time during LVAD support,
patients were effectively anticoagulated (individual range of
time 22%-100%), and in 66% of the period patients received
antiplatelet therapy (individual range 0%-100%). During a
cumulative follow-up of 4249 days, 10 clinically manifest
thromboembolic complications occurred in 8 of 23 patients
(34.8%) and 6 events of intracranial bleeding occurred in 6
patients (26.1%). This led to overall incidences of 0.24%
embolic events (0.24 events/100 LVAD-days) and 0.14%
hemorrhagic events. There was no statistical association
between the intensity of effective anticoagulation and the
occurrence of thromboembolism (P  .7). The additional
application of platelet inhibitors was likewise not associated
with a reduced incidence of thromboembolism, neither with
aspirin at 100 mg (P  .9) nor with aspirin at 330 mg in
combination with dipyridamole at 75 mg (P  .6). In a
subgroup analysis, the 6 patients with the Carmeda LVADs
Figure 1. Comparison of individual MESs with room ai
observed in all patients with external oxygen supply. Pa
18 through 23 with Carmeda devices.did not show significantly different frequencies of throm-
1162 The Journal of Thoracic and Cardiovascular Surgery ● Octboembolic events (0.49%) than did those with conventional
DeBakey LVADs (0.19%, P  .6).
A survey of the main TCD results is also given in
Table 1. A total of 499 TCD monitorings (range 3-72 per
patient) were performed. This led to an average exami-
nation rate of one TCD monitoring every 8.5 days. MESs
were detected in 20 of 23 patients (87%) and in 175
monitoring sessions (35.1%). Thus only 3 patients (13%)
remained completely free of MESs on repeated examina-
tions throughout the entire study period. The overall
mean MES number was 81.2  443 signals/h (individual
range 0-5042 signals/h), with a significant positive cor-
relation between individual prevalences and absolute
counts of MESs (P  .001). The Carmeda device was not
associated with lessening of MESs (81.8  495 signals/h,
range 0-5042 signals/h) relative to the conventional De-
Bakey LVAD (81.5  426 signals/h, range 0-4710 sig-
nals/h, P  .1).
A significant decline in MESs was evident with oxygen
application. When compared with monitoring periods while
the patient was breathing room air, both MES prevalence
(25% vs 34%, P  .01) and absolute MES counts (46.5 
283.5 vs. 104  538.4, P  .01) were significantly lower
with oxygen delivery. Strong reduction in MESs was
ts 1 through 17 were supported with regular LVADs andr and
tienduring oxygen supply. Thus at least some subset of the
ober 2005
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TXmicroemboli must be caused by cavitation processes and
therefore gaseous in nature (Figure 1).
There was no statistical association between the individ-
ual MES activity and the thromboembolic events, neither
when using the MES prevalences (P  .5) nor when using
the MES counts (P .1). Likewise, the prevalence (P .5)
and the quantity of MESs (P .3) did not correlate with the
incidence of intracranial bleeding. The MES counts were
not related to the intensity or effectiveness of anticoagula-
tion (P  .9) or to the application of antiplatelet drugs,
neither with aspirin (P .9) nor with aspirin in combination
with dipyridamole (P  .4). The 8 patients who had one
(n  6) or two (n  2) embolic events did not have
significantly higher MES prevalences (28.8%) or MES
counts (35.6  185.7/h) than did the 15 symptom-free
subjects (33.5% and 115.9  562.4 signals/h, respec-
tively, P  .5). Over time we observed a large variability
of the MES counts for both LVAD systems without a
clear towards increase or decrease of the MES activity
(Figure 2.). There was no correlation between MES ac-
tivity and patient etiology of heart failure, age, or body
mass index (all P  .8).
Discussion
The shortage of donor organs has led to expanding waiting
lists and has caused a rise in mortality among candidates for
cardiac transplantation.25 Consequently, mechanical circula-
tory support by different types of devices is now a standard
clinical procedure for bridging to transplantation. Recently, the
novel continuous axial-flow DeBakey LVAD has been intro-
duced to clinical practice.10 Certain properties of this device
are believed to reduce its thrombogenicity: (1) There is no
compliance volume shifting chamber. (2) No residual blood
volume remains in the device. (3) The rapid rotation of the
impeller ensures fast blood flow.26 (4) The specific coating of
the newest types of pumps with the Carmeda system may
additionally inhibit thrombus formation.27
The aims of this study were to assess the amount of MES
detected by TCD and to evaluate their clinical relevance in
patients with the nonpulsatile DeBakey LVAD. In two
previous studies on patients supported with the pulsatile
Novacor LVAD, Nabavi and associates15,28 reported a sig-
nificant correlation between individual MES activity and the
clinical manifestation of thromboembolism. Repeated TCD
monitoring allowed identification of patients at low risk of
clinical thromboembolism. In this study of patients with the
DeBakey LVAD, however, we found large quantities of
circulating microemboli in roughly every third of 499 ex-
aminations during a cumulative follow-up of almost 12
years. Individual peak counts were as high as 5042 signals/h
(1 signal/s), with an overall mean count of 81 MESs per
hour, compared with only 2 MES per 30 minutes in patients
with the Novacor device.15 Remarkably, we were unable to
The Journal of Thoracicfind a correlation between this very high microembolic
activity and clinical course. Patients with a higher MES
activity did not show a higher risk of thromboembolic
complications. In 2 patients (cases 6 and 11) with clinical
stroke events, we could not detect any MESs at all during
their LVAD time. In fact, the very low incidence of clini-
cally apparent embolism (0.24%) made a valid statistical
analysis difficult. In addition, the high numbers of micro-
emboli in our LVAD population could not be related to
hemostaseologic alterations. MES rates were completely
independent of mode and intensity of anticoagulation or
antiplatelet therapy. Even the DeBakey device with the
Carmeda system was not associated with reduced MESs.
Recently, unlike these findings with the DeBakey
LVAD, we have reported on low MES activity (0.5 sig-
nals/30 min.) in stroke-free patients with severe left ven-
tricular dysfunction not being supported with any LVAD.12
Thus low cardiac output with reduced left ventricular func-
tion appeared to be an independent risk factor for micro-
embolic generation.
Gaseous microemboli have been well described in pa-
tients with different types of prosthetic cardiac valves.29,30
Their gaseous nature has been nicely proved by use of the
oxygen inhalation method, leading to almost disappearance
of MES in patients with prosthetic cardiac valves.20,21 Ac-
cordingly, we likewise noted a significant drop in MES
counts of more than 50% with oxygen delivery in our
patients with DeBakey LVADs. Thus there is strong evi-
dence that most microemboli in our patient cohort are
gaseous and not solid. Summarizing all our very latest
results, we suggest that microemboli in patients with the
pulsatile Novacor LVAD are predominantly solid and carry
the risk of thromboembolism, whereas microemboli in pa-
tients with the continuous-flow DeBakey LVAD are most
likely gaseous in nature and induced by the cavitation
processes.
Still, there are important reasons to perform MES detec-
tion in patients supported with DeBakey LVADs. First, it is
totally unclear why some patients obviously did not produce
microemboli at all, whereas in others as many as several
thousands per hour appeared. Moreover, some patients had
a strongly fluctuating microembolic activity, whereas others
had a more or less continuous release. Most likely, proper-
ties of the LVAD dynamics play a critical role in the
generation of microemboli. We are currently investigating
whether certain pump characteristics (eg, power, speed, and
output) are associated with increased generation of micro-
emboli. Thus MES monitoring may support technical re-
finements in LVAD technology. Second, in patients with
prosthetic heart valves31 and those undergoing heart sur-
gery,32,33 it has been demonstrated that the quantity of gaseous
microembolization is associated with cognitive impairment
and neuropsychologic dysfunction. Apparently, a high level of
and Cardiovascular Surgery ● Volume 130, Number 4 1163
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TXFigure 2. Time course of microemboli in 23 patients supported with DeBakey LVADs. On vertical axis, average
number of MESs per hour in a week is given; that did not show significant change with time. A, Results of patients
with regular LVAD systems. B, Results of those with Carmeda devices. Because only 4 patients with regular LVADs
had support longer than 40 weeks and only 1 with Carmeda device had support longer than 20 weeks, time axes
were restricted to 40 weeks and 20 weeks, respectively.1164 The Journal of Thoracic and Cardiovascular Surgery ● October 2005
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TXclinically “silent” microembolization is not as benign as it
seems. More sophisticated clinical methods, including repeated
neuropsychologic testing, are needed to investigate whether
continuous microembolization may produce cortical dysfunc-
tion, resulting in chronic encephalopathy. Especially if perma-
nent LVAD support is being considered, the quantity of cere-
bral microemboli may be an additional criterion to identify
suitable candidates for heart transplantation. Finally, even with
oxygen delivery and subsequent suppression of cavitation-
induced microemboli, large MES counts persisted. Thus a
certain fraction of microemboli could still be solid, caused by
in situ thrombosis within the native heart or the LVAD. There
are several promising new techniques under development that
allow classification of MESs according to their acousticophysi-
cal properties. In the near future, we will be able to identify the
fraction of solid microemboli composed of platelets and plas-
matic coagulants. Then we can assess whether hemodynamic,
rheologic, or rather inflammatory parameters are involved in
the generation of solid microemboli in patients receiving
LVAD support.
So far, there is only one other study available on MES
detection in patients with DeBakey LVADs. Potapov and
colleauges16 conducted serial MES detection during the first 10
weeks after implantation of this device. Whereas we observed
MESs in 20 of 23 patients (87%), they found MESs only in
1 of 5 patients (20%). We can only speculate about the
reasons for the discrepancy between our study and the
results from Potapov and colleauges.16 In both studies,
technical equipment was appropriate and MES identifica-
tion was based on generally accepted criteria. Thus meth-
odologic factors are unlikely to account for the difference.
Most likely, the differing results reflect the large intersub-
ject and intrasubject variability of microembolism in pa-
tients receiving LVAD support. More centers should scien-
tifically address silent microembolization in such patients to
further increase our knowledge in this important issue.
In summary, we identified a high level of clinically silent
cerebral microemboli in most patients supported with the
DeBakey LVAD. Several pieces of evidence indicate that
the bulk of these microemboli are gaseous and created by
cavitation effects within the LVAD system. Although most
patients remained free of stroke symptoms, it needs to be
investigated whether continuous microembolization could
have deleterious effects on cognitive or neuropsychologic
functions.
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